Results 141 to 150 of about 3,401,781 (173)

Need for Aligning the Definition and Reporting of Cytokine Release Syndrome (CRS) in Immuno-Oncology Clinical Trials [PDF]

open access: yesCytotherapy, 2022
As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety of adverse events that may accompany CRS and for ...
Elad Sharon, Jeff Allen, Mark Stewart
exaly   +5 more sources

Management of Cytokine Release Syndrome (CRS) and HLH [PDF]

open access: yes, 2022
AbstractCytokine release syndrome (CRS) is caused by a rapid and mild to massive release of cytokines from immune cells involved in immune reactions, particularly after immunotherapy. The frequency and severity of CRS after CAR-T cell therapy varies between products (any grade: 37–93%, G3/4: 1–23%) (Neelapu et al. 2017; Schuster et al.
Ulrich Jaeger
exaly   +3 more sources

Severe Cases of Local Cytokine Release Syndrome (CRS); Craniocervical Edema Soon After Chimeric Antigen T-Cell (CAR-T) Therapy [PDF]

open access: yesOxford Medical Case Reports
Craniocervical edema appears soon after chimeric antigen receptor T-cell (CAR-T) therapy in some cases. This phenomenon is often observed right after systemic cytokine release syndrome (CRS), and it is called local CRS (L-CRS).
Akifumi Takaori-Kondo   +2 more
exaly   +4 more sources

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration

Blood, 2023
Introduction: Teclistamab is a T-cell redirecting bispecific antibody that targets both CD3 on the T-cell surface and B-cell maturation antigen (BCMA) expressed on myeloma cells. Teclistamab gained accelerated approval for RRMM patients that had previously been treated with 4 prior lines of therapy including a PI, IMID and a CD38 ...
Ellen Marin   +9 more
openaire   +1 more source

Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)

Bone Marrow Transplantation, 2020
International ...
Wallet, Florent   +7 more
openaire   +3 more sources

Overview on the Use of IL-6 Agents in the Treatment of Patients With Cytokine Release Syndrome (CRS) and Pneumonitis Related to COVID-19 Disease [PDF]

open access: yesExpert Opinion on Investigational Drugs, 2020
A novel coronavirus pneumonia (COVID-19) has caused significant life loss and healthcare burden globally. COVID-19 is known to cause a cytokine release syndrome (CRS) like response, and interleukin-6 (IL-6) is one of the cytokines involved. Clinicians are using IL-6 inhibitors to CRS, and researchers are investigating the use of IL-6 inhibitors, namely
Christina Price, Zeyun Zhou
exaly   +3 more sources

Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)

Blood, 2023
Background Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell boosting immunotherapies.
Emma Searle   +5 more
openaire   +1 more source

Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered by Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS

Blood, 2016
Abstract Background: Cytokine release syndrome (CRS) in the setting of CAR T cell therapy manifests as a wide constellation of symptoms with multi-organ involvement. CRS can vary from a mild, self-limited course to a life-threatening systemic inflammatory response which, in severe cases, may be associated with manifestations similar to ...
Crystal Mackall   +2 more
exaly   +2 more sources

Towards a safer CD19 CART therapy with reduced risk of cytokine release syndrome (CRS).

Journal of Clinical Oncology, 2016
3049Background: Despite remarkable clinical success, adoptive T-cell therapy (ACT) with anti-CD19 chimeric antigen rector (CAR) T cells is hindered by both pro-inflammatory and immuno-suppressive a...
Lucas H. Horan, Cheng Liu
openaire   +1 more source

Home - About - Disclaimer - Privacy